Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.31 |
| ▸ | CA9 | Q16790 | 4/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18488392 | 0.93 | CA12 (0.31) | CA12CA9CA1CA2 | |
| SCHEMBL18449785 | 0.86 | — | — | |
| SCHEMBL18487524 | 0.84 | NFKB1 (0.33) | — | |
| SCHEMBL15748009 | 0.84 | — | — | |
| SCHEMBL8512235 | 0.84 | CA12 (0.42) | CA12CA9CA1CA2 | |
| SCHEMBL18555563 | 0.84 | CA12 (0.42) | CA12CA9CA1CA2 | |
| SCHEMBL17190433 | 0.77 | NFKB1 (0.31) | — | |
| SCHEMBL21250272 | 0.76 | — | — | |
| SCHEMBL17192527 | 0.76 | BCHE (0.33) | — | |
| SCHEMBL17190436 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3911416-B1 | SUBSTITUTED QUINAZOLINES AS NLRP3 MODULATORS, FOR USE IN THE TREATMENT OF CANCER | INNATE TUMOR IMMUNITY INC (US) | 2024-06-12 | — | — | EP | disclosed |
| EP-3347355-B1 | HETEROTRICYCLIC SULFONAMIDES AS ANTI-CANCER AGENTS | ICAHN SCHOOL MED MOUNT SINAI (US) | 2022-07-13 | — | — | EP | disclosed |
| US-20220089571-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2022-03-24 | — | — | US | disclosed |
| CN-108349961-B | Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents | 西奈山伊坎医学院 | 2022-02-18 | — | — | CN | disclosed |
| EP-3911416-A1 | SUBSTITUTED QUINAZOLINES AS NLRP3 MODULATORS, FOR USE IN THE TREATMENT OF CANCER | Innate Tumor Immunity, Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| US-10759790-B2 | Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents | ICHAN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2020-09-01 | — | — | US | disclosed |
| WO-2020150113-A1 | SUBSTITUTED QUINAZOLINES AS NLRP3 MODULATORS, FOR USE IN THE TREATMENT OF CANCER | INNATE TUMOR IMMUNITY, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| US-10450282-B2 | Stereospecific process for 3-heterocyclylcycloaliphatic-1,2-diols | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-10-22 | — | — | US | disclosed |
| US-10221158-B2 | Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-03-05 | — | — | US | disclosed |
| US-20180251444-A1 | HETEROCYCLIC CONSTRAINED TRICYCLIC SULFONAMIDES AS ANTI-CANCER AGENTS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2018-09-06 | — | — | US | disclosed |
| US-20180251456-A1 | HETEROCYCLIC CONSTRAINED TRICYCLIC SULFONAMIDES AS ANTI-CANCER AGENTS | ICHAN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2018-09-06 | — | — | US | disclosed |
| EP-3347355-A1 | HETEROCYCLIC CONSTRAINED TRICYCLIC SULFONAMIDES AS ANTI-CANCER AGENTS | Icahn School of Medicine at Mount Sinai (US) | 2018-07-18 | — | — | EP | disclosed |
| EP-3331867-A1 | STEREOSPECIFIC PROCESS FOR 3-HETEROCYCLYLCYCLOALIPHATIC-1,2-DIOLS | Icahn School of Medicine at Mount Sinai (US) | 2018-06-13 | — | — | EP | disclosed |
| WO-2017044575-A1 | CONSTRAINED BENZHYDRYL SULFONAMIDES AS ANTICANCER AND NEUROPROTECTIVE AGENTS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2017-03-16 | — | — | WO | disclosed |
| WO-2017044572-A1 | RING CONSTRAINED DIARYLAMINO SULFONAMIDES AS ANTI-CANCER AGENTS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2017-03-16 | — | — | WO | disclosed |
| WO-2017044571-A1 | TRICYCLIC SULTAM SULFONAMIDES AS ANTICANCER AND NEUROPROTECTIVE AGENTS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2017-03-16 | — | — | WO | disclosed |
| WO-2017044569-A1 | HETEROCYCLIC CONSTRAINED TRICYCLIC SULFONAMIDES AS ANTI-CANCER AGENTS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2017-03-16 | — | — | WO | disclosed |
| WO-2017024229-A1 | STEREOSPECIFIC PROCESS FOR 3-HETEROCYCLYLCYCLOALIPHATIC-1,2-DIOLS | ICAHN SCHOOL OF MEDECINE AT MOUNT SINAI (US) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089571-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, PYCARD | CA12 4681/4885CA9 4674/4885CA1 4704/4885 |
| US-20180251444-A1 | HETEROCYCLIC CONSTRAINED TRICYCLIC SULFONAMIDES AS ANTI-CANCER AGENTS | FOXO1, HDAC3, HDAC6 | CA12 3393/4885CA9 3747/4885CA1 2978/4885 |
| US-10759790-B2 | Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents | FOXO1, HDAC3, HDAC6 | CA12 3393/4885CA9 3747/4885CA1 2978/4885 |
| US-10450282-B2 | Stereospecific process for 3-heterocyclylcycloaliphatic-1,2-diols | DDT, ODC1, CBR1 | CA12 451/4885CA9 1144/4885CA1 177/4885 |
| US-20180251456-A1 | HETEROCYCLIC CONSTRAINED TRICYCLIC SULFONAMIDES AS ANTI-CANCER AGENTS | FOXO1, HDAC3, HDAC6 | CA12 3393/4885CA9 3747/4885CA1 2978/4885 |
| US-10221158-B2 | Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents | FOXO1, HDAC3, HDAC6 | CA12 3393/4885CA9 3747/4885CA1 2978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.